Technical Analysis for TRVI - Trevi Therapeutics, Inc.

Grade Last Price % Change Price Change
grade F 3.79 -6.42% -0.26
TRVI closed down 6.42 percent on Thursday, October 17, 2019, on 2.18 times normal volume.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent N/A Down Down
See historical TRVI trend table...

Date Alert Name Type % Chg
Inside Day Range Contraction 0.00%
Wide Bands Range Expansion 0.00%
20 DMA Resistance Bearish -6.42%
Wide Bands Range Expansion -6.42%
Fell Below 20 DMA Bearish -4.17%
Fell Below 50 DMA Bearish -4.17%
Wide Bands Range Expansion -4.17%
Gapped Down Weakness -4.17%
Crossed Above 50 DMA Bullish -19.36%
MACD Bullish Signal Line Cross Bullish -19.36%

Older signals for TRVI ...

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Profile
Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of nalbuphine ER to treat serious neurologically mediated conditions. Trevi is currently developing nalbuphine ER for the treatment of chronic pruritus, chronic cough in patients with idiopathic pulmonary fibrosis (IPF) and levodopa-induced dyskinesia (LID) in patients with Parkinson’s disease. These conditions share a common pathophysiology that is mediated through opioid receptors in the central and peripheral nervous systems. Trevi is currently conducting a Phase 2b/3 clinical trial of nalbuphine ER, referred to as the PRISM trial, in patients with severe pruritus associated with prurigo nodularis. Founded in 2011, Trevi Therapeutics is headquartered in New Haven, CT.
Biopharmaceutical Organ Systems Chemical Compounds Organic Compounds Analgesics Morphinans Ethers Idiopathic Pulmonary Fibrosis Phenols Parkinson’s Disease Chronic Cough Levodopa Induced Dyskinesia Prurigo
Is TRVI a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 2 bearish and 3 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 10.62
52 Week Low 3.26
Average Volume 10,712
200-Day Moving Average 0.0
50-Day Moving Average 4.5469
20-Day Moving Average 4.2248
10-Day Moving Average 4.0495
Average True Range 0.5082
ADX 15.6
+DI 22.0116
-DI 26.6393
Chandelier Exit (Long, 3 ATRs ) 4.0353
Chandelier Exit (Short, 3 ATRs ) 4.7846
Upper Bollinger Band 4.899
Lower Bollinger Band 3.5506
Percent B (%b) 0.18
BandWidth 31.916304
MACD Line -0.2006
MACD Signal Line -0.2031
MACD Histogram 0.0025
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 4.27
Resistance 3 (R3) 4.31 4.19 4.19
Resistance 2 (R2) 4.19 4.07 4.17 4.16
Resistance 1 (R1) 3.99 3.99 3.93 3.95 4.14
Pivot Point 3.87 3.87 3.84 3.85 3.87
Support 1 (S1) 3.67 3.75 3.61 3.63 3.44
Support 2 (S2) 3.55 3.67 3.53 3.42
Support 3 (S3) 3.35 3.55 3.39
Support 4 (S4) 3.31